Abstract
The novel antibiotic MBX-500, dosed at 100, 200, or 400 mg/kg twice daily for 7 days, was evaluated for the treatment of Clostridium difficile infection (CDI) in the gnotobiotic pig model. MBX-500 increased survival at all doses and at high doses improved clinical signs and reduced lesion severity, similar to vancomycin. Our results show that MBX-500 is an effective antibiotic for the treatment of diarrhea associated with CDI and prevents severe systemic disease.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Clostridioides difficile / pathogenicity*
-
Clostridium Infections / drug therapy*
-
Colon / microbiology
-
Colon / pathology
-
Diarrhea / drug therapy*
-
Diarrhea / microbiology
-
Disease Models, Animal
-
Drug Evaluation, Preclinical
-
Fluoroquinolones / pharmacology*
-
Germ-Free Life
-
Kaplan-Meier Estimate
-
Pyrimidinones / pharmacology*
-
Severity of Illness Index
-
Swine
-
Treatment Outcome
-
Vancomycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Fluoroquinolones
-
MBX-500
-
Pyrimidinones
-
Vancomycin